All In Biotech

NDA 022259 · Hill Dermaceuticals

Tolak

Fluorouracil · Topical · Nucleoside Metabolic Inhibitor

Last checked: Nov 20, 2026Latest source record: Aug 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Sep 18, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,755

1,167 Phase 3, 630 recruiting

FAERS reports

77,744

73,787 serious, 10,973 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 6, 2022.

Tolak (fluorouracil) Cream is indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Tolak (fluorouracil) Cream, 4%, is a nucleoside metabolic inhibitor indicated for the topical treatment of actinic keratosis lesions of the face, ears, and scalp ( 1 ).

Mechanism: There is evidence that the metabolism of fluorouracil in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid. In this manner, fluorouracil interferes with the synthesis of DNA and to a lesser extent inhibits the formation of RNA. Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency that provokes unbalanced growth and death of the cell. The effects of DNA and RNA deprivation are most marked on those cells that grow more rapidly and take up fluorouracil at a more rapid rate.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TOLAK · FLUOROURACIL 4% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.

All 4,755 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea7,085
  • neutropenia5,296
  • nausea5,071
  • vomiting4,044
  • off label use3,630
  • neuropathy peripheral3,541
  • fatigue3,324
  • disease progression3,293
  • pyrexia3,093
  • thrombocytopenia3,036
  • febrile neutropenia2,916
  • anaemia2,612

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,695
20051,687
20061,392
20071,586
20081,848
20091,815
20101,692
20112,338
20122,862
20132,240
20141,876
20152,381
20162,755
20173,206
20184,849
20195,101
20204,268
20214,269
20225,740
20236,336
20246,005
20256,709
20265,094

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tolak (Fluorouracil)

2024 spending

$477

Beneficiaries

12

12 claims

Per beneficiary

$40

$0.99 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$477

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,452 on PubMed

Sponsor: Hill Dermaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.